May 23, 2017

Selexis SA and OSE Immunotherapeutics Sign Commercial License Agreement to Further Advance Development of OSE’s Interleukin Receptor 7 Antagonist

Read More
May 11, 2017

Selexis SA Opens New World-Class Laboratory Facility and Corporate Headquarters in Geneva, Switzerland

Read More
March 20, 2017

Selexis Announces Launch of Novel Cell Selection Platform Designed to Help Advance Difficult-to-Express Protein Therapeutics to the Clinic

Read More
March 14, 2017

Selexis Announces Participation at Several Upcoming Industry Conferences

Read More
February 21, 2017

Selexis to Develop Cell Lines for Three Sanofi Biologics Programs Using Selexis SUREtechnology Platform™

Read More